Antibody-Based and Cell Therapies for Advanced Mastocytosis: Established and Novel Concepts
International Journal of Molecular Sciences · 2023
DOI: 10.3390/ijms242015125 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Peter Valent und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, 1090 Vienna, Austria. Hauptthemen laut MEDLINE: Mastocytosis, Mastocytosis, Systemic. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 81 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Austrian Science Fund FWF.
Abstract (Originalsprache)
Advanced systemic mastocytosis (SM) is a heterogeneous group of myeloid neoplasms characterized by an uncontrolled expansion of mast cells (MC) in one or more internal organs, SM-induced tissue damage, and poor prognosis. Advanced SM can be categorized into aggressive SM (ASM), MC leukemia (MCL), and SM with an associated hematologic neoplasm (SM–AHN). In a vast majority of all patients, neoplastic cells display a KIT mutation, mostly D816V and rarely other KIT variants. Additional mutations in other target genes, such as SRSF2, ASXL1, or RUNX1, may also be identified, especially when an AHN is present. During the past 10 years, improved treatment approaches have led to a better quality of life and survival in patients with advanced SM. However, despite the availability of novel potent inhibitors of KIT D816V, not all patients enter remission and others relapse, often with a multi-mutated and sometimes KIT D816V-negative disease exhibiting multi-drug resistance. For these patients, (poly)chemotherapy, antibody-based therapies, and allogeneic hematopoietic stem cell transplantation may be viable treatment alternatives. In this article, we discuss treatment options for patients with drug-resistant advanced SM, including novel KIT-targeting drugs, antibody-based drugs, and stem cell-eradicating therapies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, 1090 Vienna, Austria.
- Ludwig Boltzmann Institute for Hematology and Oncology, Medical University of Vienna, 1090 Vienna, Austria.
- Division of Allergy and Clinical Immunology, University of Michigan, Ann Arbor, MI 48106, USA.
- Department of Hematological Biology, Pitié-Salpêtrière Hospital, Sorbonne University, 75013 Paris, France.
- Division of Hematology, Medical University of Graz, 8010 Graz, Austria.
- Service d'Hématologie, Imagine Institute Université de Paris, INSERM U1163, Centre National de Référence des Mastocytoses, Hôpital Necker, Assistance Publique Hôpitaux de Paris, 75015 Paris, France.
ORCID-Profile: Peter Valent, Michel Arock, Daniel Ivanov, Alberto Orfao
Förderung
- Austrian Science Fund FWF
Zitieren
APA
Valent, P., Akin, C., Arock, M., Gleixner, K. V., Greinix, H., Hermine, O., Horny, H. P., Ivanov, D., Orfao, A., Rabitsch, W., Reiter, A., Schulenburg, A., Sotlar, K., Sperr, W. R., & Ustun, C. (2023). Antibody-Based and Cell Therapies for Advanced Mastocytosis: Established and Novel Concepts. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms242015125
Vancouver
Valent P, Akin C, Arock M, Gleixner KV, Greinix H, Hermine O, et al. Antibody-Based and Cell Therapies for Advanced Mastocytosis: Established and Novel Concepts. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms242015125
BibTeX
@article{Valent2023,
author = {Valent, Peter and Akin, Cem and Arock, Michel and Gleixner, Karoline V and Greinix, Hildegard and Hermine, Olivier and Horny, Hans-Peter and Ivanov, Daniel and Orfao, Alberto and Rabitsch, Werner and Reiter, Andreas and Schulenburg, Axel and Sotlar, Karl and Sperr, Wolfgang R and Ustun, Celalettin},
title = {Antibody-Based and Cell Therapies for Advanced Mastocytosis: Established and Novel Concepts},
journal = {International Journal of Molecular Sciences},
year = {2023},
doi = {10.3390/ijms242015125}
}
EUVIMED